The current recommendations for the treatment of patients with type 2 diabetes mellitus (T2DM) emphasize the need to target multiple pathophysiologic targets of the disease and, therefore, 2 or more agents may be needed to achieve the optimal hemoglobin A1C (A1C) goal. To that end, clinicians should recommend agents that have complementary and additive mechanisms of action, such as basal insulin plus a glucagon-like peptide-1 receptor agonist (GLP-1 RA), which together address both fasting plasma glucose (FPG) and postprandial glocose (PPG) while minimizing adverse effects such as hypoglycemia. Recent clinical trials have also documented the benefits of these 2 injectable medications delivered in a fixed-ratio-delivery injectable pen, which may provide greater convenience for patients and better adherence.
Diabetologists, endocrinologists, internists, family/general practitioners, nurse practitioners, physician assistants, certified diabetes educators, and other clinicians involved in the care of patients with diabetes
At the conclusion of this activity, participants should be better able to:
Identify the advantages and limitations of GLP-1 RAs
Explain the advantages and limitations of basal insulin
Compare the clinically relevant characteristics of GLP-1 RAs
Assess the advantages and limitations of treating T2DM with a fixed-ratio combination of insulin plus a short-acting GLP-1 vs administering those agents as separate injections
Individualize T2DM management strategies to meet patients’ treatment goals with consideration for both FPG and PPG, to minimize adverse effects of treatment, and to promote adherence
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Vivian Fonseca, MD Professor of Medicine and Pharmacology Tullis-Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center New Orleans, LA
Dr. Fonseca has received research grants from Abbott, Asahi Kasei Pharma America, Eli Lilly, GI Dynamics, Inc., Gilead Sciences, Inc., and Novo Nordisk. He has received consultant fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, Nestlé Health Science - Pamlab, Inc., and Sanofi-Aventis.
Guillermo Umpierrez, MD Professor of Medicine Emory University Section Head Diabetes and Endocrinology Grady Health System Atlanta, GA
Dr. Umpierrez has received research grants from AstraZeneca, Merck & Co., Novo Nordisk, and Sanofi US and consulting fees from Sanofi US.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of HME and Sanofi US. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.